Landmark Trial Shows 60% Drop in Hospital-Acquired Pneumonia
New evidence presented at ESCMID Global 2026 reveals that structured oral hygiene programs dramatically reduce nonventilator hospital-acquired pneumonia risk.
A major new study unveiled at ESCMID Global 2026 is reshaping how healthcare teams view oral care in hospital settings. The large, multi-centre randomized controlled trial, spanning nearly 9,000 patients, demonstrated that improving oral hygiene protocols reduced the incidence of nonventilator-associated hospital-acquired pneumonia (NV-HAP) by approximately 60%.
NV-HAP, which develops in hospitalized patients who are not on ventilators, is a significant but often under-recognized threat. It contributes to longer hospital stays, higher costs, and increased mortality. Despite its impact, prevention strategies have historically lacked strong clinical evidence until now.
The Hospital-Acquired Pneumonia Prevention (HAPPEN) Study introduced a straightforward but structured intervention: patients received oral hygiene supplies and education upon admission, while staff were trained and supported to deliver consistent oral care. The results were striking. Oral care delivery increased from just 15.9% under usual care to 61.5% during the intervention phase, with patients receiving care an average of 1.5 times daily.
This improvement translated into a measurable clinical outcome: NV-HAP rates dropped from 1.00 to 0.41 cases per 100 admission days. The mechanism is clear, reducing oral bacterial load lowers the risk of aspiration-related infections originating from a patient’s own microbiota.
These findings reinforce the systemic importance of oral health. Beyond the operatory, oral hygiene is a critical component of medical care and a powerful, evidence-based tool for saving lives. Click here to read more.
